SecBot SecBot
8-K ·Filed Nov 17, 2026

PCRX

Pacira BioSciences, Inc.
MIXED
Impact 8/10
Horizonimmediate Processed4d 21h ago SEC0001140361-26-044354
Killer combo: M&A completed + management change
Actionable Insight ◆ Mixed

The deal is closed and the stock will be delisted. Noteholders should evaluate the conversion window (through January 8, 2027) for the make-whole premium of $1,103.89 per $1,000 principal versus the post-period conversion value of $922.54.

DirectionMixed
Confidencehigh
Horizonimmediate

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Viatris completed its acquisition of Pacira BioSciences via a tender offer and subsequent merger. The $1.69 billion all-cash deal closed on November 17, 2026, with Pacira becoming a wholly owned subsidiary of Viatris. The filing also covers delisting from Nasdaq, termination of Pacira's credit agreement, changes to convertible note terms, and the departure of all prior directors and officers.

Key Financial Metrics

Deal Value
$1.7B
Deal Type
merger

Key Facts

  • Viatris completed acquisition of Pacira for $36.50 per share in cash, total consideration ~$1.69 billion
  • Tender offer closed with 32,929,780 shares (66.46%) validly tendered
  • Merger completed under Section 251(h) of DGCL without stockholder vote
  • Pacira became a wholly owned subsidiary of Viatris at the Effective Time
  • All prior directors and officers of Pacira ceased; John Miraglia and Michael Rainerman became officers/directors of the surviving corporation
  • Pacira requested delisting from Nasdaq and deregistration under Section 12(b) of the Exchange Act
  • $287.5 million in 2.125% Convertible Senior Notes due 2029 modified: conversion right changed to cash based on $36.50 per share
  • Credit agreement with Wells Fargo repaid in full ($96,392.50) and terminated
  • Capped call transactions unwound for cash payments to Pacira
  • Third amended and restated certificate of incorporation and fourth amended and restated bylaws adopted

Financial Impact

Total consideration of approximately $1.69 billion for the acquisition, including repayment of certain indebtedness. $287.5 million in convertible notes outstanding; conversion rights changed to cash settlement at $36.50 per share.

revenueepsdebtdilution

Risk Factors

  • Stockholder lawsuits challenging disclosure adequacy in the tender offer are pending
  • Delisting from Nasdaq will eliminate liquidity for remaining public shareholders
  • Convertible noteholders who do not convert within the make-whole period will receive significantly less cash

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-044354
Document: ef20085678_8k.htm0001140361-26-044354
Document: ef20085678_ex3-1.htm0001140361-26-044354
Document: ef20085678_ex4-1.htm0001140361-26-044354
Document: ef20085678_ex99-1.htm0001140361-26-044354
Document: 0001140361-26-044354-index-headers.html0001140361-26-044354
Document: 0001140361-26-044354-index.html0001140361-26-044354
Document: 0001140361-26-044354.txt0001140361-26-044354

Track record

33 reports on PCRX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 17, 20264d ago 8-K Mixed 8/10 Viewing Entry $36.48 Now $36.48 −0.00% settles Dec 16
  2. Nov 17, 20264d ago SC 14D-9/A Mixed 8/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
  3. Nov 17, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
  4. Nov 17, 20264d ago 25-NSE Neutral 1/10 Entry $36.48 Now $36.48 −0.00% settles Dec 16
  5. Nov 12, 20269d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
  6. Nov 12, 20269d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  7. Nov 12, 20269d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
  8. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
  9. Nov 3, 202618d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
  10. Oct 30, 202622d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
Showing 10 of 33

US Market Status

Market Closed · Opens Mon (25h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 17, 2026